Paltusotine in Carcinoid Syndrome
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
CLINICALTRIALS.GOV IDENTIFIER: NCT05361668
SPONSOR: Crinetics Pharmaceuticals Inc.
Dr. Aman Chauhan Discusses Paltusotine in Carcinoid Syndrome
UPDATE: On Sept 10, 2023, Crinetics Pharmaceuticals announced positive results for their paltusotine phase 3 acromegaly study. This is the same once-daily pill that is currently in a phase 2 study for NET patients with carcinoid syndrome. To read the announcement, go to https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/.
Crinetics is sponsoring a phase 2 study to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
Crinetics Clinical Trials